ABT-239
ABT-239[edit | edit source]
ABT-239 is a potent and selective histamine H3 receptor antagonist that has been studied for its potential therapeutic effects in various neurological disorders. The compound was developed by Abbott Laboratories and has been the subject of research due to its ability to enhance cognitive function and wakefulness.
Mechanism of Action[edit | edit source]
ABT-239 functions by blocking the histamine H3 receptor, which is primarily found in the central nervous system. The H3 receptor acts as an autoreceptor and heteroreceptor, modulating the release of various neurotransmitters such as histamine, acetylcholine, norepinephrine, and dopamine. By inhibiting this receptor, ABT-239 increases the release of these neurotransmitters, which can enhance cognitive processes and alertness.
Potential Therapeutic Uses[edit | edit source]
Research has suggested that ABT-239 may be beneficial in treating conditions such as attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, and schizophrenia. Its ability to improve cognitive performance and memory makes it a candidate for addressing cognitive deficits associated with these disorders.
Cognitive Enhancement[edit | edit source]
Studies have shown that ABT-239 can improve learning and memory in animal models. This has led to interest in its potential use as a cognitive enhancer in humans, particularly for individuals with cognitive impairments.
Wakefulness Promotion[edit | edit source]
ABT-239 has also been investigated for its effects on sleep-wake regulation. By increasing the release of neurotransmitters involved in wakefulness, it may help in managing conditions characterized by excessive daytime sleepiness.
Development and Research[edit | edit source]
Although ABT-239 showed promise in preclinical studies, its development was halted due to concerns about its safety profile. However, the research on ABT-239 has paved the way for the development of other H3 receptor antagonists with improved safety and efficacy.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
